A Phase II Trial of Personalized Immunotherapy in Patients (pts) with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M HNSCC) That Have Progressed on Prior Immunotherapy

被引：0
|
作者：
Zandberg, D. P. [1 ]
Chen, J. [2 ]
Tatsuoka, C. [2 ]
Normolle, D. P. [3 ]
Ohr, J. [2 ]
Isett, B.
Rahman, Z. [2 ,5 ]
Fenton, M. [6 ]
Gooding, W. [7 ]
Vujanovic, L. [4 ]
Bao, R. [8 ]
Marsh, C. [2 ]
Seastone, D. [2 ]
Gorantla, V. [1 ]
Pabla, S. [9 ]
Conroy, J.
Ferris, R. L. [5 ]
机构：
[1] Univ Pittsburgh, Div Hematol & Oncol, Dept Med, Med Ctr, Pittsburgh, PA USA
[2] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[3] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA
[4] Univ Pittsburgh, Pittsburgh, PA USA
[5] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[6] UPMC, Pittsburgh, PA USA
[7] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA USA
[8] UPMC, Div Hematol Oncol, Hillman Canc Ctr, Pittsburgh, PA USA
[9] Labcorp Oncol, Buffalo, NY USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 118卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4
引用
收藏
页码：E4 / E4
页数：1
相关论文
共 50 条
  • [1] The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC).
    Scheff, Nicole N.
    Nilsen, Marci Lee
    Li, Jinhong
    Harris, Alexandria L.
    Swartz, Andrew
    Hsieh, Ronan Wenhan
    Anderson, Jennifer Lynn
    Ferris, Robert L.
    Menk, Ashley
    Delgoffe, Greg M.
    Zandberg, Dan Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Efficacy of cetuximab based chemotherapy after immunotherapy treatments (IT) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
    Hernando-Calvo, A.
    Mirallas, O.
    Marmolejo, D.
    Felip, E.
    Garralda, E.
    Villacampa Javierre, G.
    Feliu, B.
    Martinez, S.
    Gutierrez, R.
    Dienstmann, R.
    Brana, I.
    ANNALS OF ONCOLOGY, 2019, 30 : 59 - 59
  • [3] Nutritional status (NS) as a strong predictor for immunotherapy (IT) outcome in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
    Hernando-Calvo, A.
    Mirallas, O.
    Marmolejo Castaneda, D. H.
    Vieito, M.
    Santa Gadea, O. Saavedra
    Gardeazabal, I.
    Villacampa Javierre, G.
    Aguilar, S.
    Martin Liberal, J.
    Bescos, C.
    Lorente, J.
    Giralt, J.
    Benavente, S.
    Fuentes, J. F.
    Temprana-Salvador, J.
    Alberola, M.
    Dienstmann, R.
    Garralda, E.
    Felip, E.
    Brana, I.
    ANNALS OF ONCOLOGY, 2020, 31 : S671 - S672
  • [4] Clinical biomarkers as predictors of immunotherapy (IT) benefit in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pt)
    Hernando-Calvo, A.
    Mirallas, O.
    Marmolejo, D.
    Felip, E.
    Villacampa Javierre, G.
    Garralda, E.
    Gutierrez, R.
    Feliu, B.
    Martinez, S.
    Dienstmann, R.
    Brana, I.
    ANNALS OF ONCOLOGY, 2019, 30 : 25 - 25
  • [5] Genomic characteristics and immunotherapy outcomes in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
    Park, J. C.
    Cortes, M. Useche
    Durbeck, J.
    Clark, J. R.
    Zhao, Y.
    Saladi, S. V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S856 - S856
  • [6] Next generation sequencing (NGS) helps predict response to immunotherapy (IO) in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
    Mirallas, O.
    Marmolejo Castaneda, D. H.
    Illescas, D. G.
    Gomez-Puerto, D.
    Berche, R.
    Calvo, A. H.
    Vieito Villar, M.
    Lorini, L.
    Navarro, V.
    Assaf Pastrana, J. D.
    Saavedra, O.
    Alonso, G.
    Aguilar Izquierdo, S.
    Bescos, C.
    Lorente, J.
    Giralt, J.
    Dienstmann, R.
    Garralda, E.
    Felip, E.
    Brana, I.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S856 - S857
  • [7] Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
    Lasniska, Izabela
    Kolenda, Tomasz
    Teresiak, Anna
    Lamperska, Katarzyna M.
    Galus, Lukasz
    Mackiewicz, Jacek
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (03) : 290 - 303
  • [8] Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
    Hsieh, Ronan W.
    Borson, Steven
    Tsagianni, Anastasia
    Zandberg, Dan P.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [9] Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck
    Saada-Bouzid, Esma
    Peyrade, Frederic
    Guigay, Joel
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (03) : 146 - 151
  • [10] Phase II study of temsirolimus and erlotinib in patients (pts) with recurrent/metastatic (R/M), platinum-refractory head and neck squamous cell carcinoma (HNSCC)
    Bauman, Julie E.
    Arias-Pulido, Hugo
    Lee, Sang-Joon
    Considine, Michael
    Fekrazad, M. Houman
    Howard, Jason
    Bishop, Justin A.
    Olson, Garth T.
    Jones, Dennie V.
    Fertig, Elana J.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345